StockData
DexCom Inc logo

DexCom Inc (DXCM) stock

DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3030% below fair value
$80.19−2.33 (-2.82%)

Close on Nov 19, 2026Market cap $29.91BP/E 31.6Yield –

DexCom net income

Net income is the profit left for shareholders after every expense, interest and tax.

DexCom's net income for the twelve months ending Sep 30, 2026 was $991.00M, up 37.5% year over year. For fiscal 2025 it was $836.30M, up 45.1% from the year before. The highest annual figure on record is $836.30M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$836.30M+45.1%
FY2024Dec 31, 2024$576.20M+6.4%
FY2023Dec 31, 2023$541.50M+58.7%
FY2022Dec 31, 2022$341.20M+57.3%
FY2021Dec 31, 2021$216.90M-60.5%
FY2020Dec 31, 2020$549.70M+443.7%
FY2019Dec 31, 2019$101.10M–
FY2018Dec 31, 2018-$127.10M–
FY2017Dec 31, 2017-$50.20M–
FY2016Dec 31, 2016-$65.60M–
FY2015Dec 31, 2015-$57.60M–
FY2014Dec 31, 2014-$22.40M–
FY2013Dec 31, 2013-$29.80M–
FY2012Dec 31, 2012-$54.50M–
FY2011Dec 31, 2011-$44.70M–
FY2010Dec 31, 2010-$55.20M–
FY2009Dec 31, 2009-$53.52M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$275.10M-3.1%
Q2 FY2026Jun 30, 2026$249.10M+38.5%
Q1 FY2026Mar 31, 2026$199.50M+89.3%
Q4 FY2025Dec 31, 2025$267.30M+76.2%
Q3 FY2025Sep 30, 2025$283.80M+110.8%
Q2 FY2025Jun 30, 2025$179.80M+25.3%
Q1 FY2025Mar 31, 2025$105.40M-28.0%
Q4 FY2024Dec 31, 2024$151.70M-40.8%
Q3 FY2024Sep 30, 2024$134.60M+11.5%
Q2 FY2024Jun 30, 2024$143.50M+23.8%
Q1 FY2024Mar 31, 2024$146.40M+201.2%
Q4 FY2023Dec 31, 2023$256.30M+179.2%
Q3 FY2023Sep 30, 2023$120.70M+19.3%
Q2 FY2023Jun 30, 2023$115.90M+127.7%
Q1 FY2023Mar 31, 2023$48.60M-50.1%
Q4 FY2022Dec 31, 2022$91.80M–
Q3 FY2022Sep 30, 2022$101.20M+15.9%
Q2 FY2022Jun 30, 2022$50.90M-35.1%
Q1 FY2022Mar 31, 2022$97.30M+72.2%
Q4 FY2021Dec 31, 2021-$5.30M-101.3%
Q3 FY2021Sep 30, 2021$87.30M+20.9%
Q2 FY2021Jun 30, 2021$78.40M+69.3%
Q1 FY2021Mar 31, 2021$56.50M+183.9%
Q4 FY2020Dec 31, 2020$411.30M+343.7%
Q3 FY2020Sep 30, 2020$72.20M+57.6%
Q2 FY2020Jun 30, 2020$46.30M–
Q1 FY2020Mar 31, 2020$19.90M–
Q4 FY2019Dec 31, 2019$92.70M–
Q3 FY2019Sep 30, 2019$45.80M-1.7%
Q2 FY2019Jun 30, 2019-$10.50M-134.8%
Q1 FY2019Mar 31, 2019-$26.90M–
Q4 FY2018Dec 31, 2018-$179.70M–
Q3 FY2018Sep 30, 2018$46.60M–
Q2 FY2018Jun 30, 2018$30.20M+941.4%
Q1 FY2018Mar 31, 2018-$24.20M–
Q4 FY2017Dec 31, 2017-$9.40M–
Q3 FY2017Sep 30, 2017-$2.00M–
Q2 FY2017Jun 30, 2017$2.90M–
Q1 FY2017Mar 31, 2017-$41.70M–
Q4 FY2016Dec 31, 2016-$7.40M–

More DexCom figures

See a number that looks wrong?